<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7022795/results/search/test_trace/results.xml">
  <result pre="(http://creativecommons.org/licenses/by/4.0/). Abstract In recent decades, drugs used to treat malaria" exact="infection" post="have been shown to be beneficial for many other"/>
  <result pre="viruses emerging infections 1. Introduction Antimalarial drugs used for the" exact="treatment" post="and prevention of malaria are classified in a heterogenic"/>
  <result pre="drugs have been studied, proposed, and sometimes used for the" exact="treatment" post="of other pathologies, such as cancer, autoimmune diseases, and"/>
  <result pre="A third case report of a patient with multidrug-resistant HCMV" exact="infection" post="is difficult to interpret due to the complicated series"/>
  <result pre="cases of stem cell transplant recipients who received pre-emptive AS" exact="treatment" post="for HCMV infection. Two of these showed a decrease"/>
  <result pre="AQ. No measurable difference was observed in either the HCMV" exact="detection" post="frequency or load in the blood of children in"/>
  <result pre="but also in a child affected by HHV-6B-associated myocarditis. AS" exact="treatment" post="was associated with a decrease in the levels of"/>
  <result pre="study is currently investigating a novel nonsurgical approach to the" exact="treatment" post="of HPV-associated anal intraepithelial high-grade neoplasia using AS suppositories."/>
  <result pre="study of AS vaginal inserts has been designed for the" exact="treatment" post="of women who have cervical high-grade intraepithelial neoplasia, but"/>
  <result pre="a retrospective study to assess the potential effect of this" exact="treatment" post="on the mortality of patients with EBOV. Although the"/>
  <result pre="1600s, currently still playing a pivotal role, especially in the" exact="treatment" post="of chloroquine (CQ)-resistant Plasmodium falciparum [65,66]. Due to the"/>
  <result pre="it is difficult to draw conclusions due to the challenging" exact="treatment" post="protocols and compromised health of the patients. In many"/>
  <result pre="JCPyV entry into glial cells, preventing the diffusion of the" exact="infection" post="in oligodendrocytes. The outcomes of this treatment are controversial,"/>
  <result pre="diffusion of the infection in oligodendrocytes. The outcomes of this" exact="treatment" post="are controversial, leading to the resolution of the infection,"/>
  <result pre="the infection, with a claimed effect of MQ and mirtazapine" exact="treatment" post="[86,87,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105], and to the resolution of the infection probably"/>
  <result pre="and mirtazapine treatment [86,87,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105], and to the resolution of the" exact="infection" post="probably due to other factors [96,106,107,108,109] or to the"/>
  <result pre="rarely with the death of the patient [126]. The combined" exact="treatment" post="MQ and mirtazapine was administered to HIV-positive patients, leading"/>
  <result pre="the Zika virus (ZIKV) in 2016, showing different reductions in" exact="infection" post="rate, depending on the cell model used, and different"/>
  <result pre="al. confirmed the in vitro effect of MQ on ZIKV" exact="infection" post="and evaluated it on DENV, performing several in vitro"/>
  <result pre="vitro assays [131]. Sun et al. performed an in vitro" exact="screening" post="of 795 fixed-dose drug combinations of three molecules, choosing"/>
  <result pre="properties and mechanism of action encouraged its use for the" exact="treatment" post="of different diseases. Currently, CQ and its hydroxy-analog hydroxychloroquine"/>
  <result pre="extensively discussed. In particular, CQ/hydroxyCQ have been used for the" exact="treatment" post="of emerging chikungunya virus (CHIKV) infection, recently causing numerous"/>
  <result pre="outbreaks in the world. Khan et al. showed that the" exact="treatment" post="of infected Vero cells with different micromolar concentrations of"/>
  <result pre="the high viremia measured at the acute stage of CHIKV" exact="infection" post="(up to 1010 virus copies/mL serum) [37]. Sourisseau and"/>
  <result pre="to evaluate the efficacy and safety of CQ for the" exact="treatment" post="of CHIKV infection in 2006 in French Reunion Island"/>
  <result pre="efficacy and safety of CQ for the treatment of CHIKV" exact="infection" post="in 2006 in French Reunion Island (Indian Ocean). No"/>
  <result pre="small to draw definitive conclusions regarding the efficacy of CQ" exact="treatment" post="(Table 1) [37]. Aminoquinolines were proposed for the treatment"/>
  <result pre="CQ treatment (Table 1) [37]. Aminoquinolines were proposed for the" exact="treatment" post="of other viral infections, such as ZIKV. In 2017,"/>
  <result pre="and an improvement in the well-being of patients with DENV" exact="infection" post="but did not alter the duration of the disease"/>
  <result pre="was reviewed to clarify the efficacy of CQ in the" exact="treatment" post="of filovirus infection [144]. It was concluded that the"/>
  <result pre="clarify the efficacy of CQ in the treatment of filovirus" exact="infection" post="[144]. It was concluded that the efficacy of CQ"/>
  <result pre="and spread of coronavirus (CoV) in vitro and to prevent" exact="infection" post="with CoV in newborn mice. Since the suppressive effect"/>
  <result pre="and its analogs have effects against HCV. In particular, the" exact="treatment" post="of JFH-1 or Huh-7 cells with CQ reduced HCV"/>
  <result pre="or Huh-7 cells with CQ reduced HCV entry, replication, and" exact="infection" post="in a dose-dependent manner [148,149,150]. Furthermore, CQ, in combination"/>
  <result pre="trials were initiated to verify the efficacy of the combination" exact="treatment" post="of hydroxyCQ and ribavirin, but no results were posted"/>
  <result pre="decrease in CD4 number [41]. Another double-blind, randomized placebo-controlled trial" exact="testing" post="the effects of CQ in 13 chronically HIV-infected persons"/>
  <result pre="results showed that the administration of CQ during chronic HIV" exact="infection" post="resulted in decreased immune activation, but no data regarding"/>
  <result pre="patients were recruited. However, CQ was not shown to prevent" exact="infection" post="with IAV (Table 1) [38]. CQ had inhibitory effects"/>
  <result pre="demonstrated the potential of CQ as an antiviral in the" exact="treatment" post="of hand, foot, and mouth disease caused by EV"/>
  <result pre="infection. The positive results obtained in the murine model of" exact="infection" post="were indicative of the fact that CQ may mitigate"/>
  <result pre="was originally developed and has been widely used for the" exact="treatment" post="of malaria. However, subsequent studies revealed that it was"/>
  <result pre="a Ugandan strain of ZIKV by immunostaining the envelope after" exact="treatment" post="and infection and subsequent plaque assay in different cells."/>
  <result pre="strain of ZIKV by immunostaining the envelope after treatment and" exact="infection" post="and subsequent plaque assay in different cells. These data"/>
  <result pre="a human placenta tissue model, with a dose-dependent reduction in" exact="infection" post="and virion production by the Ugandan strain [166]. 5.2."/>
  <result pre="envelope proteins to prevent viral entry. Using an innovative visual" exact="screening" post="approach coupling computational studies and biologic assays on ten"/>
  <result pre="exerted its antiviral activity at the early-mid stage of VSV" exact="infection" post="[170]. These results indicated a different mode of action"/>
  <result pre="with no effects on virus titers, suggesting that the antibiotic" exact="treatment" post="was able to alleviate severe influenza pneumonia symptoms [171]."/>
  <result pre="The sulfadoxine-pyrimethamine combination is used in some settings for the" exact="treatment" post="of uncomplicated malaria in pregnant women, and it is"/>
  <result pre="uncertain. Among the aryl-aminoalcohols, the use of MQ in the" exact="treatment" post="of JCPyV infection has been extensive, although with contradictory"/>
  <result pre="aryl-aminoalcohols, the use of MQ in the treatment of JCPyV" exact="infection" post="has been extensive, although with contradictory outcomes. Among the"/>
  <result pre="trials on the use of AS against HPV for the" exact="treatment" post="of anal and cervical intraepithelial high-grade neoplasia. Based on"/>
  <result pre="malaria in the Amazon regionRev. Soc. Bras. Med. Trop.20104350851110.1590/S0037-8682201000050000721085859 7.SalamN.MustafaS.HafizA.ChaudharyA.A.DeebaF.ParveenS.Global" exact="prevalence" post="and distribution of coinfection of malaria, dengue and chikungunya:"/>
  <result pre="potent antiviral agent in a patient with late drug-resistant cytomegalovirus" exact="infection" post="after hematopoietic stem cell transplantationClin. Infect. Dis.2008461455145710.1086/58710618419454 13.WolfD.G.ShimoniA.ResnickI.B.StammingerT.NeumannA.U.ChouS.EfferthT.CaplanO.RoseJ.NaglerA.et al.Human"/>
  <result pre="with artesunate exhibit reduced rates of proliferation and human cytomegalovirus" exact="infection" post="in vitroJ. Thorac. Dis.201571151115710.3978/j.issn.2072-1439.2015.07.0526380730 25.SchnepfN.CorvoJ.PorsM.J.MazeronM.C.Antiviral activity of ganciclovir and"/>
  <result pre="activitiesBioorg. Med. Chem.2015235452545810.1016/j.bmc.2015.07.04826260339 32.MorèreL.AndouardD.LabrousseF.SaadeF.CallisteC.A.CotinS.AubardY.RawlinsonW.D.EsclaireF.HantzS.et al.Ex vivo model of congenital cytomegalovirus" exact="infection" post="and new combination therapiesPlacenta201536414710.1016/j.placenta.2014.11.00325479789 33.DrouotE.PiretJ.BoivinG.Artesunate demonstrates in vitro synergism"/>
  <result pre="dengue-related symptomsMem. Inst. Oswaldo. Cruz.201310859659910.1590/S0074-0276201300050001023903975 37.De LamballerieX.BoissonV.ReynierJ.C.EnaultS.CharrelR.N.FlahaultA.RoquesP.Le GrandR.On chikungunya acute" exact="infection" post="and chloroquine treatmentVector Borne Zoonotic Dis.2008883783910.1089/vbz.2008.004918620511 38.PatonN.I.LeeL.XuY.OoiE.E.CheungY.B.ArchuletaS.WongG.Wilder-SmithA.SmithA.W.Chloroquine for influenza"/>
  <result pre="prevention: A randomised, double-blind, placebo controlled trialLancet Infect. Dis.20111167768310.1016/S1473-3099(11)70065-221550310 39.SperberK.LouieM.KrausT.PronerJ.SapiraE.LinS.StecherV.MayerL.Hydroxychloroquine" exact="treatment" post="of patients with human immunodeficiency virus type 1Clin. Ther.19951762263610.1016/0149-2918(95)80039-58565026"/>
  <result pre="cytomegalovirus diseaseTranspl. Infect. Dis.20151775175510.1111/tid.1243526432076 48.GermiR.MarietteC.AlainS.LupoJ.ThiebautA.BrionJ.P.EpaulardO.Saint RaymondC.MalvezziP.MorandP.Success and failure of artesunate" exact="treatment" post="in five transplant recipients with disease caused by drug-resistant"/>
  <result pre="with disease caused by drug-resistant cytomegalovirusAntivir. Res.2014101576110.1016/j.antiviral.2013.10.01424184983 49.GanttS.HuangM.L.MagaretA.BuntsL.SelkeS.WaldA.RosenthalP.J.DorseyG.CasperC.An artesunate-containing antimalarial" exact="treatment" post="regimen did not suppress cytomegalovirus viremiaJ. Clin. Virol.20135827627810.1016/j.jcv.2013.06.00823827788 50.AuerochsS.KornK.MarschallM.A"/>
  <result pre="drug artesunateJ. Clin. Virol.200946242810.1016/j.jcv.2009.05.01719501020 52.HakacovaN.KlingelK.KandolfR.EngdahlE.Fogdell-HahnA.HigginsT.First therapeutic use of Artesunate in" exact="treatment" post="of human herpesvirus 6B myocarditis in a childJ. Clin."/>
  <result pre="artemether-lumefantrine (Coartem) on cytomegalovirus urine viral load during and following" exact="treatment" post="for malaria in childrenJ. Clin. Virol.201677404510.1016/j.jcv.2016.02.00626895228 65.AchanJ.TalisunaA.O.ErhartA.YekaA.TibenderanaJ.K.BaliraineF.N.RosenthalP.J.D’AlessandroU.Quinine, an old"/>
  <result pre="old anti-malarial drug in a modern world: Role in the" exact="treatment" post="of malariaMalar. J.20111014410.1186/1475-2875-10-14421609473 66.MalakarS.SreelathaL.DechtawewatT.NoisakranS.YenchitsomanusP.T.ChuJ.J.H.LimjindapornT.Drug repurposing of quinine as antiviral"/>
  <result pre="mefloquine efficacy against JC virus in vitroAntimicrob. Agents Chemother.2009531840184910.1128/AAC.01614-0819258267 72.KishidaS.TanakaK.Mefloquine" exact="treatment" post="in a patient suffering from progressive multifocal leukoencephalopathy after"/>
  <result pre="leukoencephalopathy after umbilical cord blood transplantIntern. Med.2010492509251310.2169/internalmedicine.49.322721088359 73.GoftonT.E.Al-KhotaniA.O’FarrellB.AngL.C.McLachlanR.S.Mefloquine in the" exact="treatment" post="of progressive multifocal leukoencephalopathyJ. Neurol. Neurosurg. Psychiatry20118245245510.1136/jnnp.2009.19065220562463 74.BeppuM.KawamotoM.NukuzumaS.KoharaN.Mefloquine improved"/>
  <result pre="Neurol. Med.2014201454927110.1155/2014/54927124711940 86.ShiraiS.YabeI.KanoT.ShimizuY.SasamoriT.SatoK.HirotaniM.NonakaT.TakahashiI.MatsushimaM.et al.Usefulness of 11C-methionine-positron emission tomography for the" exact="diagnosis" post="of progressive multifocal leukoencephalopathyJ. Neurol.20142612314231810.1007/s00415-014-7500-y25223960 87.MitsikostasD.D.MastorodemosV.TsagournizakisM.KodounisA.TsagkaropoulosA.KonitsiotisS.ToulasP.PapadimitriouA.PapadimitriouD.TavernarakisA.et al.Natalizumab-related progressive multifocal"/>
  <result pre="multifocal leukoencephalopathy in an immunocompetent patientJ. Neurol. Sci.201332610711010.1016/j.jns.2013.01.01023375959 93.LindåH.von HeijneA.Presymptomatic" exact="diagnosis" post="with MRI and adequate treatment ameliorate the outcome after"/>
  <result pre="patientJ. Neurol. Sci.201332610711010.1016/j.jns.2013.01.01023375959 93.LindåH.von HeijneA.Presymptomatic diagnosis with MRI and adequate" exact="treatment" post="ameliorate the outcome after natalizumab-associated progressive multifocal leukoencephalopathyFront. Neurol.201341110.3389/fneur.2013.0001123423248"/>
  <result pre="mefloquineJ. Neurovirol.20152169470110.1007/s13365-015-0340-425916731 96.BalakD.M.W.HajdarbegovicE.BramerW.M.NeumannH.A.M.ThioH.B.Progressive multifocal leukoencephalopathy associated with fumaric acid esters" exact="treatment" post="in psoriasis patientsJ. Eur. Acad. Dermatol. Venereol.2017311475148210.1111/jdv.1423628322482 97.YoshidaH.OhshimaK.TodaJ.KusakabeS.MasaieH.YagiT.IshikawaJ.Significant improvement"/>
  <result pre="psoriasis patientsJ. Eur. Acad. Dermatol. Venereol.2017311475148210.1111/jdv.1423628322482 97.YoshidaH.OhshimaK.TodaJ.KusakabeS.MasaieH.YagiT.IshikawaJ.Significant improvement following combination" exact="treatment" post="with mefloquine and mirtazapine in a patient with progressive"/>
  <result pre="Changes: Can We Make a Diagnosis?Am. J. Case Rep.20192010110510.12659/AJCR.91152130674865 107.HarelA.HorngS.GustafsonT.RamineniA.FarberR.S.FabianM.Successful" exact="treatment" post="of progressive multifocal leukoencephalopathy with recombinant interleukin-7 and maraviroc"/>
  <result pre="archetype in cerebrospinal fluid in a MS patient with dimethylfumarate" exact="treatment" post="without lymphopenia or signs of PMLJ. Neurol.20182651880188210.1007/s00415-018-8931-729948248 119.ZuckerB.E.StacpooleS.R.L.Progressive multifocal"/>
  <result pre="Immune Reconstitution Inflammatory Syndrome (PML-IRIS): Two case reports of successful" exact="treatment" post="with mefloquine and a review of the literatureAnn. Acad."/>
  <result pre="Med. Singap.20124162062423303123 124.AdachiE.KoibuchiT.ImaiK.KikuchiT.KogaM.NakamuraH.MiuraT.IwamotoA.FujiiT.Favourable outcome of progressive multifocal leukoencephalopathy with mefloquine" exact="treatment" post="in combination with antiretroviral therapy in an HIV-infected patientInt."/>
  <result pre="region rearrangements and host immunityJ. Neurovirol.20131927427910.1007/s13365-013-0167-923715894 129.CliffordD.B.NathA.CinqueP.BrewB.J.ZivadinovR.GorelikL.ZhaoZ.DudaP.A study of mefloquine" exact="treatment" post="for progressive multifocal leukoencephalopathy: Results and exploration of predictors"/>
  <result pre="Ebola virus replication in vitro but failed to protect against" exact="infection" post="and disease in the in vivo guinea pig modelJ."/>
  <result pre="biological threat agentsPLoS ONE20138e6057910.1371/journal.pone.006057923577127 144.AkpovwaH.Chloroquine could be used for the" exact="treatment" post="of filoviral infections and other viral infections that emerge"/>
  <result pre="Biochem. Funct.20163419119610.1002/cbf.318227001679 145.VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.SeidahN.G.NicholS.T.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol. J.200526910.1186/1743-422X-2-6916115318 146.KeyaertsE.LiS.VijgenL.RysmanE.VerbeeckJ.Van RanstM.MaesP.Antiviral activity of chloroquine against"/>
  <result pre="J.200526910.1186/1743-422X-2-6916115318 146.KeyaertsE.LiS.VijgenL.RysmanE.VerbeeckJ.Van RanstM.MaesP.Antiviral activity of chloroquine against human coronavirus OC43" exact="infection" post="in newborn miceAntimicrob. Agents Chemother.2009533416342110.1128/AAC.01509-0819506054 147.KeyaertsE.VijgenL.MaesP.NeytsJ.Van RanstM.In vitro inhibition"/>
  <result pre="acidification by chloroquine analogs as a promising strategy for the" exact="treatment" post="of emerging viral diseasesPharmacol. Res. Perspect.20175e0029310.1002/prp2.29328596841 151.TsaiW.P.NaraP.L.KungH.F.OroszlanS.Inhibition of human"/>
  <result pre="chloroquineJ. Clin. Virol.20012013113510.1016/S1386-6532(00)00139-611166661 155.BoelaertJ.R.PietteJ.SperberK.The potential place of chloroquine in the" exact="treatment" post="of HIV-1-infected patientsJ. Clin. Virol.20012013714010.1016/S1386-6532(00)00140-211166662 156.SavarinoA.LuciaM.B.RastrelliE.RutellaS.GolottaC.MorraE.TamburriniE.PernoC.F.BoelaertJ.R.SperberK.et al.Anti-HIV effects of"/>
  <result pre="doxycycline against vesicular stomatitis virus in vitroFEMS Microbiol. Lett.201536210.1093/femsle/fnv195 171.NgH.H.NarasarajuT.PhoonM.C.SimM.K.SeetJ.E.ChowV.T.Doxycycline" exact="treatment" post="attenuates acute lung injury in mice infected with virulent"/>
  <result pre="overlapping resonance Rayleigh scatteringSpectrochim. Acta A Mol. Biomol. Spectrosc.201412423724210.1016/j.saa.2013.12.11424486868 173.PolatK.Y.TosunM.S.ErtekinV.AydinliB.EmreS.Brucella" exact="infection" post="with pancytopenia after pediatric liver transplantationTranspl. Infect. Dis.20121432632910.1111/j.1399-3062.2011.00709.x22260451 174.WalterM.S.FrankM.J.SatuéM.MonjoM.RønoldH.J.LyngstadaasS.P.HaugenH.J.Bioactive"/>
  <result pre="virtual screeningPLoS ONE20105e1012610.1371/journal.pone.001012620405039 183.AngiusF.PirasE.UdaS.MadedduC.SerpeR.BigiR.ChenW.DittmerD.P.PompeiR.IngianniA.Antimicrobial sulfonamides clear latent Kaposi sarcoma herpesvirus" exact="infection" post="and impair MDM2-p53 complex formationJ. Antibiot.20177096296610.1038/ja.2017.6728611469 184.CaselliE.GalvanM.SantoniF.AlvarezS.de LeraA.R.IvanovaD.GronemeyerH.CarusoA.GuidoboniM.CassaiE.et al.Retinoic"/>
  <result pre="acid analogues inhibit human herpesvirus 8 replicationAntivir. Ther.20081319920918505171 185.KrugL.T.PozharskayaV.P.YuY.InoueN.OffermannM.K.Inhibition of" exact="infection" post="and replication of human herpesvirus 8 in microvascular endothelial"/>
  <result pre="groups [37] Orthomyxoviridae IAV Chloroquine NCT01078779 No prevention of IAV" exact="infection" post="[38] Retroviridae HIV Hydroxychloroquine [39,40] Reduction in HIV-1 RNA"/>
  <result pre="Chloroquine NCT02004314 Patients did not experience any improvement after CQ" exact="treatment" post="[43] Chloroquine NCT01650558 Terminated, awaiting results [44,45] microorganisms-08-00085-t002_Table 2Table"/>
  <result pre="2Table 2 Clinical studies assessing the efficacy of Mefloquine (MQ)" exact="treatment" post="and its combinations in JCPyV-infected progressive multifocal leukoencephalopathy (PML)"/>
 </snippets>
</snippetsTree>
